GGA1: A Protein Involved in Pain and Angiogenesis (G26088)

GGA1: A Protein Involved in Pain and Angiogenesis

GGA1 (Gamma-Adaptin-Related Protein 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

GGA1 is characterized by its unique structure, which consists of a long cytoplasmic tail and a short N-terminal transmembrane domain. The cytoplasmic tail of GGA1 is composed of a series of hypervariable regions (HVRs), which are regions that are highly variable in their sequence and can play a variety of different functions in the cell. One of the HVRs of GGA1 is a putative transmembrane secretion signal (TMS) region, which is involved in the delivery of the protein to the cell surface.

GGA1 is involved in a variety of physiological processes in the body, including modulating cell signaling pathways and contributing to the development and maintenance of various diseases. One of the well-documented functions of GGA1 is its role in the regulation of pain perception. GGA1 has been shown to play a critical role in the modulation of pain sensitivity in response to tissue damage, neuroinflammation, and other forms of tissue stress.

In addition to its role in pain regulation, GGA1 is also involved in a variety of other physiological processes, including cell signaling, angiogenesis, and inflammation. For example, GGA1 has been shown to play a critical role in the regulation of cell proliferation and differentiation, and has been implicated in the development of various types of cancer. It is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed, and has been implicated in the development of various cardiovascular diseases.

GGA1 is a potential drug target and has been the subject of intense research in recent years. Several studies have demonstrated the efficacy of small molecules and other compounds that can modulate the activity of GGA1, with the goal of developing new treatments for a variety of diseases. For example, a small molecule called SID-522 has been shown to inhibit the activity of GGA1 and reduce pain sensitivity in response to tissue damage. Other studies have used similar approaches to identify a variety of other compounds that have potential as GGA1 inhibitors or modulators.

While the potential applications of GGA1 as a drug target or biomarker are significant, there are also concerns about the potential side effects and risks associated with its use. As with any drug, the development of GGA1-based treatments may require careful consideration of potential adverse effects and the need for careful monitoring of the safety of GGA1-targeted compounds.

In conclusion, GGA1 is a protein that is involved in a variety of physiological processes in the body, including modulating cell signaling pathways and contributing to the development and maintenance of various diseases. Its unique structure and multiple functions make it an attractive target for drug development, with potential applications in the treatment of a variety of conditions. While the development of GGA1-based treatments is still in its early stages, the potential impact of this protein on human health and well-being is significant.

Protein Name: Golgi Associated, Gamma Adaptin Ear Containing, ARF Binding Protein 1

Functions: Plays a role in protein sorting and trafficking between the trans-Golgi network (TGN) and endosomes. Mediates the ARF-dependent recruitment of clathrin to the TGN and binds ubiquitinated proteins and membrane cargo molecules with a cytosolic acidic cluster-dileucine (DXXLL) motif (PubMed:11301005, PubMed:15886016). Mediates export of the GPCR receptor ADRA2B to the cell surface (PubMed:27901063). Required for targeting PKD1:PKD2 complex from the trans-Golgi network to the cilium membrane (By similarity). Regulates retrograde transport of proteins such as phosphorylated form of BACE1 from endosomes to the trans-Golgi network (PubMed:15886016, PubMed:15615712)

The "GGA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GGA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC